Estrella Immunopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Six Months Ended June 30, 2026 · For the Six Months Ended June 30, 2025 | ||||
|---|---|---|---|---|
| Cash Flows from Operating Activities: | ||||
| Net loss | $(4,598,403) | $(7,649,189) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 292,012 | 318,193 | ||
| Change in fair value of derivative liabilities | 330,719 | - | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other receivables | 114,662 | 559,928 | ||
| Accounts payable - related party | (546,549) | 3,719 | ||
| Other payables and accrued liabilities | 17,145 | (90,993) | ||
| Accrued liability - related party | (4,088,334) | 5,981,666 | ||
| Franchise tax payable | - | (4,134) | ||
| Income tax payable | - | (50) | ||
| Net cash used in operating activities | (8,478,748) | (880,860) | ||
| Cash Flows from Financing Activities: | ||||
| Payments of transactions cost | (758,882) | (40,000) | ||
| Proceeds received from issuance of common stock for PIPE investment | - | 1,350,000 | ||
| Proceeds received from issuance of common stock, prefunded warrants and common stock warrants for registered direct offering | 7,999,988 | 0 | ||
| Proceeds received from exercise of prefunded warrants | 10 | - | ||
| Purchase of treasury stock | - | (29,462) | ||
| Net cash provided by financing activities | 7,241,116 | 1,280,538 | ||
| Net Change in Cash and Cash Equivalents | (1,237,632) | 399,678 | ||
| Cash and Cash Equivalents at beginning of the period | 1,384,302 | 916,916 | ||
| Cash and Cash Equivalents at end of the period | $146,670 | $1,316,594 | ||
| Supplemental Cash Flow Information | ||||
| Cash paid for income tax | $1,600 | $913 | ||
| Cash paid for interest | $ | - | $ | - |
| Supplemental Disclosure of Non-cash Financing Activities | ||||
| Recognition of derivative liabilities upon closing of the PIPE investment | $ | - | $187,941 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.